If you have been reading about Fragment designation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
TAN-821 is an opioid drug which was originally reported as an agonist for the putative ε-opioid receptor, however this is now thought not to be a separate opioid receptor in its own right but is more likely a heteromer made from hybridisation of known opioid receptor subunits. It has subsequently been shown to have potent affinity for the kappa opioid receptor.
A few locals, most notably Arkansas Gazette columnist John Brummett, also objected to the staging of a violent picture at their State Capitol, but the venue did close for filming during the second weekend of September. In a bizarre coincidence, one of its own Magnolia trees burned down during the staging of the helicopter crash. McCuen ordered that the hole be covered to conceal the mishap before it reopened to the public. Principal photography belatedly ended on September 26, 1990. However, more reshoots had to be staged in early 1991 in Los Angeles. Estimates of the film's final budget have varied. Wichard quoted it as $17 million after the mid-production reboot, but $25 million before launch. However, a Stonebridge executive reiterated at the same time that the cost-conscious production had been capped to $17 million. In August 1991, Epic Productions sued producer Yoram Ben Ami for $8 million, accusing him of being responsible for many of the film's creative and logistical woes, resulting in cost overruns that took it from a projected $7 million budget to more than $15 million. The outcome of the lawsuit was not publicized.
IGF-1, IGF receptors (IGF-1R) and IGF binding proteins (IGFBP). The therapeutic applications of IGF-1 are limited due to its poor central uptake and potential side-effects. IGF-1 that is not bound to its binding protein bears a very short half-life and is cleaved by enzymes to form the tripeptide glycine-proline-glutamate (GPE). However, the enzymatic instability of GPE, with a plasma half-life of less than 4 minutes, is further cleaved to produce the final product, cyclic-Glycine-Proline (cGP).
Both peptides have been shown "in vivo" to bind to the 93 kDa subunit of sucrose synthase, an essential component in sucrose metabolism. Sucrose degradation is a key step in nitrogen fixation, and is a pre-requisite for normal nodule development. Phytosulfokine (PSK) — was first identified as a "conditioning factor" in asparagus and carrot cell cultures. The bioactive five amino acid peptide (PSK) is proteolytically processed from an ~80 amino acid precursor secreted peptide. PSK has been demonstrated to promote cellular proliferation and transdifferentiation. It has been demonstrated that PSK binds to a membrane bound LRR receptor like kinase (PSKR). POLARIS (PLS) — The PLS peptide has a predicted length of 36 amino acids however possesses no secretion signal, suggesting that it functions within the cytoplasm. The PLS peptide itself has not yet been biochemically isolated, however loss-of-function mutants are hypersensitive to cytokinin with reduced responsiveness to auxin. Developmentally it is involved in vascularization, longitudinal cell expansion and increased radial expansion. Rapid Alkalinization Factor (RALF) — is 49 amino acid peptide that was identified whilst purifying systemin from tobacco leaves, it causes rapid medium alkanalization and does not activate defence responses like systemin. Tomato RALF precursor cDNA encodes a 115 amino acid polypeptide containing an amino-terminal signal sequence with the bioactive RALF peptide encoded at the carboxy terminus.
=== Further synthesis methods === Pyridines can also be prepared via a Mannich reaction. The products are β-aminoketones (Mannich bases). If the hydrochloride of such a base is reacted with an aldehyde and ammonium acetate, a correspondingly substituted pyridine is obtained. In the Bohlmann-Rahtz synthesis, an enamine is first added to an alkynone. A pyridine is then formed by intramolecular condensation reaction and dehydration between the ketone and the amino group. Under suitable conditions, the enamino ester can be generated in situ. For this purpose, the alkynone can be reacted with ammonium acetate, a keto ester, and an acidic catalyst such as acetic acid or zinc bromide.
Sources: en.wikipedia.org
=== Gamma === Gamma motor neurons, unlike alpha motor neurons, are not directly involved in muscle contraction. The nerves associated with these neurons do not send signals that directly adjust the shortening or lengthening of muscle fibers. However, these nerves are important in keeping muscle spindles taut.
Sarcosine, also known as N-methylglycine, or monomethylglycine, is a non-proteinogenic amino acid with the formula CH3N(H)CH2CO2H. It is the N-methyl derivative of glycine, with a secondary amine in place of the primary amine, and occurs naturally in muscles and other body tissues as an intermediate in the metabolism of choline to glycine. It was first isolated and named by the German chemist Justus von Liebig in 1847. Sarcosine is ubiquitous in biological materials. It is used in manufacturing biodegradable surfactants and toothpastes as well as in other applications. It is also a reagent in organic synthesis. It has a mildly sweet taste. Pharmacologically, sarcosine functions as a competitive inhibitor of the glycine transporter type 1 (GlyT1), a co-agonist at the glycine binding site of the NMDA receptor, and, at higher concentrations, an agonist at the strychnine-sensitive glycine receptor. These properties have led to its investigation as an adjunctive treatment in schizophrenia and major depressive disorder. Sarcosine has also been identified as an oncometabolite in prostate cancer, where elevated levels correlate with disease progression and metastatic potential.
-based regularization in a wavelet or other domain), such as via Ulf Grenander's Sieve estimator or via Bayes penalty methods or via I.J. Good's roughness method may yield superior performance to expectation-maximization-based methods which involve a Poisson likelihood function but do not involve such a prior. Attenuation correction: Attenuation occurs when photons emitted by the radiotracer inside the body are absorbed by intervening tissue between the detector and the emission of the photon. As different LORs must traverse different thicknesses of tissue, the photons are attenuated differentially. The result is that structures deep in the body are reconstructed as having falsely low tracer uptake. This must be corrected for when using quantitative PET imaging. One option for estimating attenuation coefficients is via a transmission scan, using a 68Ge rod source that is rotated around the patient Transmission scans directly measure attenuation values at 511 keV. With PET-CT scanners the 511 keV photon attenuation coefficients can be estimated using the Hounsfield units from the CT scan. Attenuation correction in PET-MRI scanners is more challenging, as the MRI images do not directly contain information on about the tissue attenuation coefficients, and the scanner bores are too narrow for a transmission scan.
Like many lichens, Xanthoria parietina produces various secondary metabolites (lichen substances), primarily anthraquinone pigments that contribute to its vivid color. Its dominant compound, parietin, is an orange-yellow anthraquinone that accumulates in the outer cortex and is sometimes referred to as physcion in chemical literature. Parietin typically makes up 2.1% of the thallus dry weight and forms a hydrophobic layer in the upper cortex above the algal layer. It is deposited as tiny crystals in the upper cortex, where it protects the photobiont. Parietin synthesis is stimulated by UV-B radiation and photosynthates from the Trebouxia symbiont. In addition to shielding against UV radiation, parietin acts as a barrier against environmental toxins, particularly heavy metals. Parietin, an anthraquinone pigment, not only gives X. parietina its bright orange color but also protects it from visible light (400–500 nm). Experimental removal of parietin led to increased photoinhibition, especially in hydrated thalli, confirming its protective function. However, when desiccated, X. parietina remained phototolerant, suggesting that structural adaptations also contribute to its light resistance. In addition to its role in photoprotection, parietin enhances desiccation tolerance by stabilizing cell membranes and modifying the upper cortex to improve water retention. Parietin is highly effective in UV protection, absorbing UV-B radiation with a peak at 288 nm. This trait is particularly beneficial in UV-intense habitats such as coastal cliffs and alpine regions.
Gregory L. Verdine (born June 10, 1959) is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability. Verdine is the co-inventor with Christian Schafmeister of stapled peptides, a new class of drugs that combines the versatile binding properties of monoclonal antibodies with the cell-penetrating ability of small molecules. Verdine coined the term "drugging the undruggable" to describe the unique capabilities of stapled peptides. A close analog of a stapled peptide drug invented in the Verdine Lab, sulanemadlin (ALRN-6924), is a first-in-class dual MDM2/MDMX inhibitor currently in Phase II clinical development by Aileron Therapeutics, which he co-founded in 2005. FogPharma, founded in 2016, aims to further develop stapled peptide technology for therapeutic use. He has founded numerous other drug discovery companies, including six that are listed on the NASDAQ. His companies have succeeded in developing two FDA-approved drugs, romidepsin and paritaprevir, which are, respectively, an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs), and an acylsulfonamide inhibitor that is used to treat chronic hepatitis C.
Sources: en.wikipedia.org
The World Bektashi Congress, also called the National Congress of the Bektashi, a conference during which members of the Bektashi Community make important decisions, has been held in Albania several times. Since 1945, it has been held exclusively in Tirana. The longest gap between two congresses lasted from 1950 to 1993, when congresses could not be held during Communist rule in Albania. A list of congresses is given below.
June 9, 2010: Law on the creation of childcare assistant centers and various provisions relating to childcare assistants. July 9, 2010: Law on violence specifically against women, domestic violence, and the impact of such violence on children. September 28, 2010: Law aimed at combating school absenteeism. October 11, 2010: Law banning the concealment of the face in public spaces. November 9, 2010: Pension reform law. January 27, 2011: Law on the balanced representation of women and men on boards of directors and supervisory boards, and on professional equality. May 24, 2011: Decree establishing a Commission on the image of women in the media. July 7, 2011: Law on bioethics. March 12, 2012: Law on access to permanent employment and improving working conditions for contract agents in the civil service, combating discrimination, and various civil service provisions. May 24, 2012: Decree on the responsibilities of the Minister for Women's Rights. August 6, 2012: Law on sexual harassment. September 28, 2012: Decree on the Interministerial Committee on Women's Rights and Gender Equality. November 30, 2012: The Interministerial Committee on Women's Rights establishes a 4-year action plan, prioritizing women's rights in public policies. December 17, 2012: Social Security Financing Law for 2013, including provisions on paternity leave. December 18, 2012: Decree on the implementation of corporate obligations regarding professional equality between women and men.
In Season 6, while in labor, Jackie is shocked when Bev reveals Jackie's birth name is actually Marjorie; the family began calling her Jackie because Roseanne, unable to pronounce the name Marjorie, instead called her baby sister "my Jackie". But in Season 10, Jackie introduces herself to Andrea, the woman looking to hire Becky as her surrogate, as Jacqueline. Despite Jackie's apparent flightiness in the early episodes, she is actually the backbone of the Conner/Harris family in many ways, as Roseanne admits in the last episode of Season 9, and which also reveals that Jackie, not Bev, had come out as a lesbian during the final season and that Roseanne knew, but had just always pictured her with a man.
{\displaystyle {\begin{aligned}{\cfrac {V_{\max }}{1+{\cfrac {\ce {[I]}}{K_{i}}}}}&={V_{\max }}\left({\cfrac {K_{i}}{K_{i}+[{\ce {I}}]}}\right)&&{\text{multiply by }}{\cfrac {K_{i}}{K_{i}}}=1\\&={V_{\max }}\left({\cfrac {K_{i}+[{\ce {I}}]-[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}\right)&&{\text{add }}[{\ce {I}}]-[{\ce {I}}]=0{\text{ to numerator}}\\&={V_{\max }}\left(1-{\cfrac {[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}\right)&&{\text{simplify }}{\cfrac {K_{i}+[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}=1\\&=V_{\max }-V_{\max }{\cfrac {\ce {[I]}}{K_{i}+[{\ce {I}}]}}&&{\text{multiply out by }}V_{\max }\end{aligned}}}
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.